Evaluation of the efficacy of novaluron 0.2 % GR for the control of Aedes (Stegomyia) aegypti (Diptera).

Aedes (Stegomyia) aegypti is the main vector of dengue, zika and chikungunya in the Americas. These diseases have a significant impact on public health. According to the World Health Organization (WHO), controlling these diseases requires a comprehensive approach, and the control of larvae is a part of that strategy. Insect growth regulator (IGR) insecticides stand out as an efficient alternative for facilitating the control of Ae. aegypti at immature stages. The main goal was to evaluate the effectiveness of IGR novaluron 0.2 % GR, in the 50, 90, 95 and 99 lethal concentrations (LC) for fourth-instar larvae of Ae. aegypti in the laboratory. In field conditions, the percentage of inhibition of emergence was estimated by using the LC levels obtained in the laboratory through two methods of water management with refill and without refill in 40 L recipients. The study was carried out in 30 homes in a neighborhood with a high incidence of dengue in Medellin (Antioquia, Colombia). The bioassays completed indicated that LC 50, 90, 95 and 99 corresponded to 0.019, 0.055, 0.065 and 0.084 mg/L, respectively. The field results indicated that novaluron 0.2 % GR efficiently inhibited the emergence of adult Ae. aegypti, suggesting that the product has potential as a population regulator at very low concentrations. The product is considered extremely useful for programs to prevent and control dengue, zika and chikungunya

Primary immunodeficiency and autoimmunity: A comprehensive review

The primary immunodeficiency diseases (PIDs) include many genetic disorders that affect different components of the innate and adaptive responses. The number of distinct genetic PIDs has increased exponentially with improved methods of detection and advanced laboratory methodology. Patients with PIDs have an increased susceptibility to infectious diseases and non-infectious complications including allergies, malignancies and autoimmune diseases (ADs), the latter being the first manifestation of PIDs in several cases. There are two types of PIDS. Monogenic immunodeficiencies due to mutations in genes involved in immunological tolerance that increase the predisposition to develop autoimmunity including polyautoimmunity, and polygenic immunodeficiencies characterized by a heterogeneous clinical presentation that can be explained by a complex pathophysiology and which may have a multifactorial etiology. The high prevalence of ADs in PIDs demonstrates the intricate relationships between the mechanisms of these two conditions. Defects in central and peripheral tolerance, including mutations in AIRE and T regulatory cells respectively, are thought to be crucial in the development of ADs in these patients. In fact, pathology that leads to PID often also impacts the Treg/Th17 balance that may ease the appearance of a proinflammatory environment, increasing the odds for the development of autoimmunity. Furthermore, the influence of chronic and recurrent infections through molecular mimicry, bystander activation and super antigens activation are supposed to be pivotal for the development of autoimmunity. These multiple mechanisms are associated with diverse clinical subphenotypes that hinders an accurate diagnosis in clinical settings, and in some cases, may delay the selection of suitable pharmacological therapies. Herein, a comprehensively appraisal of the common mechanisms among these conditions, together with clinical pearls for treatment and diagnosis is presented. © 2019 Elsevier Lt

Primary immunodeficiency and autoimmunity: A comprehensive review

The primary immunodeficiency diseases (PIDs) include many genetic disorders that affect different components of the innate and adaptive responses. The number of distinct genetic PIDs has increased exponentially with improved methods of detection and advanced laboratory methodology. Patients with PIDs have an increased susceptibility to infectious diseases and non-infectious complications including allergies, malignancies and autoimmune diseases (ADs), the latter being the first manifestation of PIDs in several cases. There are two types of PIDS. Monogenic immunodeficiencies due to mutations in genes involved in immunological tolerance that increase the predisposition to develop autoimmunity including polyautoimmunity, and polygenic immunodeficiencies characterized by a heterogeneous clinical presentation that can be explained by a complex pathophysiology and which may have a multifactorial etiology. The high prevalence of ADs in PIDs demonstrates the intricate relationships between the mechanisms of these two conditions. Defects in central and peripheral tolerance, including mutations in AIRE and T regulatory cells respectively, are thought to be crucial in the development of ADs in these patients. In fact, pathology that leads to PID often also impacts the Treg/Th17 balance that may ease the appearance of a proinflammatory environment, increasing the odds for the development of autoimmunity. Furthermore, the influence of chronic and recurrent infections through molecular mimicry, bystander activation and super antigens activation are supposed to be pivotal for the development of autoimmunity. These multiple mechanisms are associated with diverse clinical subphenotypes that hinders an accurate diagnosis in clinical settings, and in some cases, may delay the selection of suitable pharmacological therapies. Herein, a comprehensively appraisal of the common mechanisms among these conditions, together with clinical pearls for treatment and diagnosis is presented. © 2019 Elsevier Lt

Evaluación de la eficacia de novaluron 0,2 % GR para el control de Aedes (Stegomyia) aegypti (Diptera)

Aedes (Stegomyia) aegypti is the main vector of dengue, zika and chikungunya in the Americas. These diseases have a significant impact on public health. According to the World Health Organization (WHO), controlling these diseases requires a comprehensive approach, and the control of larvae is a part of that strategy. Insect growth regulator (IGR) insecticides stand out as an efficient alternative for facilitating the control of Ae. aegypti at immature stages. The main goal was to evaluate the effectiveness of IGR novaluron 0.2 % GR, in the 50, 90, 95 and 99 lethal concentrations (LC) for fourth-instar larvae of Ae. aegypti in the laboratory. In field conditions, the percentage of inhibition of emergence was estimated by using the LC levels obtained in the laboratory through two methods of water management with refill and without refill in 40 L recipients. The study was carried out in 30 homes in a neighborhood with a high incidence of dengue in Medellin (Antioquia, Colombia). The bioassays completed indicated that LC 50, 90, 95 and 99 corresponded to 0.019, 0.055, 0.065 and 0.084 mg/L, respectively. The field results indicated that novaluron 0.2 % GR efficiently inhibited the emergence of adult Ae. aegypti, suggesting that the product has potential as a population regulator at very low concentrations. The product is considered extremely useful for programs to prevent and control dengue, zika and chikungunya.Aedes (Stegomyia) aegypti es el vector principal de dengue, zika y chikungunya en las Américas, enfermedades de gran impacto en salud pública. De acuerdo con la Organización Mundial de la Salud (OMS), el control de estas enfermedades requiere un enfoque integral, y el control larvario hace parte de tal estrategia. Con base en ello, los Insecticidas Reguladores de Crecimiento (IRC) surgen como una alternativa eficiente para el control de los estados inmaduros de este mosquito. Con el propósito de evaluar la eficacia del IRC novaluron 0,2 % GR se determinaron en laboratorio las concentraciones letales (CL) 50, 90, 95 y 99 sobre larvas de cuarto estadio de Ae. aegypti , y en condiciones de campo se estimó el porcentaje de inhibición de emergencia empleando las CL obtenidas en laboratorio, mediante dos esquemas de manejo de agua, con recambio y sin recambio, en recipientes de 40 L, en 30 viviendas en un barrio de Medellín (Antioquia, Colombia) con alta incidencia de dengue. Los bioensayos indicaron que las CL 50, 90, 95 y 99 correspondieron a 0,019; 0,055; 0,065 y 0,084 mg/L, respectivamente. Los resultados de campo revelan que novaluron 0,2 % GR inhibió eficientemente la emergencia de adultos de Ae. aegypti indicando el potencial del producto como regulador de poblaciones a muy bajas concentraciones. Se considera que el producto es de gran utilidad en los programas de prevención y control de dengue, zika y chikungunya

Juvenile polyautoimmunity in a rheumatology setting

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Patients were systematically interviewed and their medical records reviewed using a questionnaire that sought information about demographic, clinical, immunological, and familial characteristics. A hierarchical cluster analysis was done to determine similarities between autoimmune diseases based on PolyA. PolyA occurred simultaneously in 138 (44%) patients. Multiple autoimmune syndrome was observed in 62 (19.8%) patients. There were 25 index diseases of which, systemic lupus erythematosus (SLE, n = 134, 42.8%), juvenile idiopathic arthritis (JIA, n = 40, 12.7%), Hashimoto's thyroiditis (HT, n = 24, 7.66%), immune thrombocytopenic purpura (ITP n = 20, 6.39%), antiphospholipid syndrome (APS, n = 15, 4.79%), and vitiligo (VIT, n = 15, 4.79%) were the most frequent and represented 79.23% of the total number of patients. Familial autoimmunity influenced PolyA. A high aggregation of autoimmunity was observed (? r = 3.5). Three main clusters were identified, of which SLE and APS were the most similar pair of diseases (based on the Jaccard index) followed by HT and JIA, which were related to ITP and Sjögren's syndrome. The third cluster was composed of localized scleroderma and VIT. Our findings may assist physicians to make an early diagnosis of this frequent condition. Pediatric patients with ADs should be systematically assessed for PolyA. © 201

Juvenile polyautoimmunity in a rheumatology setting

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Patients were systematically interviewed and their medical records reviewed using a questionnaire that sought information about demographic, clinical, immunological, and familial characteristics. A hierarchical cluster analysis was done to determine similarities between autoimmune diseases based on PolyA. PolyA occurred simultaneously in 138 (44%) patients. Multiple autoimmune syndrome was observed in 62 (19.8%) patients. There were 25 index diseases of which, systemic lupus erythematosus (SLE, n = 134, 42.8%), juvenile idiopathic arthritis (JIA, n = 40, 12.7%), Hashimoto's thyroiditis (HT, n = 24, 7.66%), immune thrombocytopenic purpura (ITP n = 20, 6.39%), antiphospholipid syndrome (APS, n = 15, 4.79%), and vitiligo (VIT, n = 15, 4.79%) were the most frequent and represented 79.23% of the total number of patients. Familial autoimmunity influenced PolyA. A high aggregation of autoimmunity was observed (? r = 3.5). Three main clusters were identified, of which SLE and APS were the most similar pair of diseases (based on the Jaccard index) followed by HT and JIA, which were related to ITP and Sjögren's syndrome. The third cluster was composed of localized scleroderma and VIT. Our findings may assist physicians to make an early diagnosis of this frequent condition. Pediatric patients with ADs should be systematically assessed for PolyA. © 201

Caracterización molecular de genes Cry y efectos biológicos de la delta endotoxina de cepas de bacillus thuringiensis (berline) recolectadas de diferentes regiones de Colombia

IP 1101-12-005-93Parte del documento en inglésInternational Workshop on Transgenic Technology in Plants(1994). -- [s.l.: s.n.], 1994. -- p. ; 29 cm.;PONENCIA(S) EN CONGRESO: Genetic engineering of insect resistance in agricultural crops by expression of;Bacillus thuringiensis delta-endotoxin genes / Orlando Acosta.-- p. 1-19.'-- en: Proceedings of th